{"id":473570,"date":"2021-04-08T08:42:15","date_gmt":"2021-04-08T12:42:15","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=473570"},"modified":"2021-04-08T08:42:15","modified_gmt":"2021-04-08T12:42:15","slug":"shareholder-alert-lowey-dannenberg-p-c-investigates-claims-on-behalf-of-investors-of-cytodyn-inc-and-encourages-investors-to-contact-the-firm","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-lowey-dannenberg-p-c-investigates-claims-on-behalf-of-investors-of-cytodyn-inc-and-encourages-investors-to-contact-the-firm\/","title":{"rendered":"SHAREHOLDER ALERT: Lowey Dannenberg, P.C., Investigates Claims on Behalf of Investors of CytoDyn Inc. and Encourages Investors to Contact the Firm"},"content":{"rendered":"<div class=\"mw_release\">\n<p>NEW YORK, April  08, 2021  (GLOBE NEWSWIRE) &#8212; Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating claims of violations of federal securities laws on behalf of investors of CytoDyn Inc. (\u201cCytoDyn\u201d or the \u201cCompany\u201d) (OTCMKTS: CYDY).<\/p>\n<p>CytoDyn Inc. is a biotech company primarily focused on the development and commercialization of a drug named Leronlimab.<\/p>\n<p>On\u00a0March 5, 2021, CytoDyn issued a press release providing an update on its product &#8220;Vyrologix (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications.&#8221;\u00a0 The press release stated, in part, that &#8220;the Phase 3 trial of leronlimab for the treatment of severe-to-critical patients with COVID-19 demonstrated continued safety, substantial improvement in the survival rate, and faster hospital discharge in critically ill COVID-19 patients.&#8221;\u00a0 Although the press release touted purportedly positive results, industry observers and analysts quickly characterized the Company&#8217;s press release as misleading.\u00a0 For example, on\u00a0March 8, 2021,\u00a0<em>Seeking Alpha\u00a0<\/em>published an article by\u00a0Paul Santos\u00a0entitled &#8220;CytoDyn: Parsing Failure.&#8221;\u00a0 The article asserted that Cytodyn&#8217;s &#8220;leronlimab Phase 3 trial on COVID-19 severe-to-critical patients failed . . . to meet both its primary endpoint and all secondary endpoints with any statistical significance&#8221; and described the Company as having effectively &#8220;buried&#8221; the results in its press release.\u00a0 Santos noted that &#8220;[a] normal biotech company would have stated this clearly, both in its PR titles and in their text bodies. Cytodyn, however, did something else.&#8221;\u00a0<\/p>\n<p>As the market digested the actual significance of CytoDyn&#8217;s announcement, the Company&#8217;s stock price fell\u00a0$1.70\u00a0per share, or 41.98%, over the following two trading sessions, closing at\u00a0$2.35\u00a0per share on\u00a0March 9, 2021.<\/p>\n<p>The Complaint alleges that through the use of Company press releases and other information released by CytoDyn\u2019s partners, CytoDyn has released, or caused to be released, materially false and misleading statements in violation of the federal securities laws.<\/p>\n<p>If you are a shareholder of CytoDyn who purchased CytoDyn securities between March 27, 2020 and March 9, 2021, inclusive, you have until May 11, 2021 to ask the Court to appoint you as Lead Plaintiff for the class. To participate, learn more, or discuss the issues surrounding the investigation, please contact our attorneys at (914) 733-7256 or via email at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ARvnyMPedyjREOsKZy_bJEdTTD9FGQ0Ng8hJB-P9hjHj7BwhItGFQwc8LXe1GplHWgXyvIQwfRbBmFaf1IF4WjKe9UNJllt4CbWplEgGhvg=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>investigations@lowey.com<\/u><\/a>.\u00a0\u00a0<\/p>\n<p>\n        <strong>Whistleblowers: <\/strong>Persons with non-public information regarding CytoDyn should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.<\/p>\n<p>\n        <strong>About Lowey Dannenberg<\/strong>\n      <\/p>\n<p>Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has previously recovered billions of dollars on behalf of investors.<\/p>\n<p>\n        <strong>Contact<\/strong>\n      <\/p>\n<p>Lowey Dannenberg P.C.<br \/>44 South Broadway, Suite 1100\u00a0<br \/>White Plains, NY 10601<br \/>Tel: (914) 733-7256<br \/>Email:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ARvnyMPedyjREOsKZy_bJEdTTD9FGQ0Ng8hJB-P9hjHkesxHKnsnWJE2OHxQHM3iBiDr5z9iWS4-rNBZmxwQKdkbY55W96LNnx9qOxuCYNg=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">investigations@lowey.com<\/a><\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMzcyNSM0MTExOTU4IzIxOTQ1MzQ=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/6810f495-94b2-4121-b3ea-59aecc738593\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, April 08, 2021 (GLOBE NEWSWIRE) &#8212; Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating claims of violations of federal securities laws on behalf of investors of CytoDyn Inc. (\u201cCytoDyn\u201d or the \u201cCompany\u201d) (OTCMKTS: CYDY). CytoDyn Inc. is a biotech company primarily focused on the development and commercialization of a drug named Leronlimab. On\u00a0March 5, 2021, CytoDyn issued a press release providing an update on its product &#8220;Vyrologix (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications.&#8221;\u00a0 The press release stated, in part, that &#8220;the Phase 3 trial of leronlimab for the treatment of severe-to-critical patients with COVID-19 demonstrated continued safety, substantial improvement in the survival rate, and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-lowey-dannenberg-p-c-investigates-claims-on-behalf-of-investors-of-cytodyn-inc-and-encourages-investors-to-contact-the-firm\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;SHAREHOLDER ALERT: Lowey Dannenberg, P.C., Investigates Claims on Behalf of Investors of CytoDyn Inc. and Encourages Investors to Contact the Firm&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-473570","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SHAREHOLDER ALERT: Lowey Dannenberg, P.C., Investigates Claims on Behalf of Investors of CytoDyn Inc. and Encourages Investors to Contact the Firm - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-lowey-dannenberg-p-c-investigates-claims-on-behalf-of-investors-of-cytodyn-inc-and-encourages-investors-to-contact-the-firm\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SHAREHOLDER ALERT: Lowey Dannenberg, P.C., Investigates Claims on Behalf of Investors of CytoDyn Inc. and Encourages Investors to Contact the Firm - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, April 08, 2021 (GLOBE NEWSWIRE) &#8212; Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating claims of violations of federal securities laws on behalf of investors of CytoDyn Inc. (\u201cCytoDyn\u201d or the \u201cCompany\u201d) (OTCMKTS: CYDY). CytoDyn Inc. is a biotech company primarily focused on the development and commercialization of a drug named Leronlimab. On\u00a0March 5, 2021, CytoDyn issued a press release providing an update on its product &#8220;Vyrologix (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications.&#8221;\u00a0 The press release stated, in part, that &#8220;the Phase 3 trial of leronlimab for the treatment of severe-to-critical patients with COVID-19 demonstrated continued safety, substantial improvement in the survival rate, and &hellip; Continue reading &quot;SHAREHOLDER ALERT: Lowey Dannenberg, P.C., Investigates Claims on Behalf of Investors of CytoDyn Inc. and Encourages Investors to Contact the Firm&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-lowey-dannenberg-p-c-investigates-claims-on-behalf-of-investors-of-cytodyn-inc-and-encourages-investors-to-contact-the-firm\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-08T12:42:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMzcyNSM0MTExOTU4IzIxOTQ1MzQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-lowey-dannenberg-p-c-investigates-claims-on-behalf-of-investors-of-cytodyn-inc-and-encourages-investors-to-contact-the-firm\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-lowey-dannenberg-p-c-investigates-claims-on-behalf-of-investors-of-cytodyn-inc-and-encourages-investors-to-contact-the-firm\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SHAREHOLDER ALERT: Lowey Dannenberg, P.C., Investigates Claims on Behalf of Investors of CytoDyn Inc. and Encourages Investors to Contact the Firm\",\"datePublished\":\"2021-04-08T12:42:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-lowey-dannenberg-p-c-investigates-claims-on-behalf-of-investors-of-cytodyn-inc-and-encourages-investors-to-contact-the-firm\\\/\"},\"wordCount\":493,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-lowey-dannenberg-p-c-investigates-claims-on-behalf-of-investors-of-cytodyn-inc-and-encourages-investors-to-contact-the-firm\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMzcyNSM0MTExOTU4IzIxOTQ1MzQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-lowey-dannenberg-p-c-investigates-claims-on-behalf-of-investors-of-cytodyn-inc-and-encourages-investors-to-contact-the-firm\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-lowey-dannenberg-p-c-investigates-claims-on-behalf-of-investors-of-cytodyn-inc-and-encourages-investors-to-contact-the-firm\\\/\",\"name\":\"SHAREHOLDER ALERT: Lowey Dannenberg, P.C., Investigates Claims on Behalf of Investors of CytoDyn Inc. and Encourages Investors to Contact the Firm - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-lowey-dannenberg-p-c-investigates-claims-on-behalf-of-investors-of-cytodyn-inc-and-encourages-investors-to-contact-the-firm\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-lowey-dannenberg-p-c-investigates-claims-on-behalf-of-investors-of-cytodyn-inc-and-encourages-investors-to-contact-the-firm\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMzcyNSM0MTExOTU4IzIxOTQ1MzQ=\",\"datePublished\":\"2021-04-08T12:42:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-lowey-dannenberg-p-c-investigates-claims-on-behalf-of-investors-of-cytodyn-inc-and-encourages-investors-to-contact-the-firm\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-lowey-dannenberg-p-c-investigates-claims-on-behalf-of-investors-of-cytodyn-inc-and-encourages-investors-to-contact-the-firm\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-lowey-dannenberg-p-c-investigates-claims-on-behalf-of-investors-of-cytodyn-inc-and-encourages-investors-to-contact-the-firm\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMzcyNSM0MTExOTU4IzIxOTQ1MzQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMzcyNSM0MTExOTU4IzIxOTQ1MzQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-lowey-dannenberg-p-c-investigates-claims-on-behalf-of-investors-of-cytodyn-inc-and-encourages-investors-to-contact-the-firm\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SHAREHOLDER ALERT: Lowey Dannenberg, P.C., Investigates Claims on Behalf of Investors of CytoDyn Inc. and Encourages Investors to Contact the Firm\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SHAREHOLDER ALERT: Lowey Dannenberg, P.C., Investigates Claims on Behalf of Investors of CytoDyn Inc. and Encourages Investors to Contact the Firm - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-lowey-dannenberg-p-c-investigates-claims-on-behalf-of-investors-of-cytodyn-inc-and-encourages-investors-to-contact-the-firm\/","og_locale":"en_US","og_type":"article","og_title":"SHAREHOLDER ALERT: Lowey Dannenberg, P.C., Investigates Claims on Behalf of Investors of CytoDyn Inc. and Encourages Investors to Contact the Firm - Market Newsdesk","og_description":"NEW YORK, April 08, 2021 (GLOBE NEWSWIRE) &#8212; Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating claims of violations of federal securities laws on behalf of investors of CytoDyn Inc. (\u201cCytoDyn\u201d or the \u201cCompany\u201d) (OTCMKTS: CYDY). CytoDyn Inc. is a biotech company primarily focused on the development and commercialization of a drug named Leronlimab. On\u00a0March 5, 2021, CytoDyn issued a press release providing an update on its product &#8220;Vyrologix (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications.&#8221;\u00a0 The press release stated, in part, that &#8220;the Phase 3 trial of leronlimab for the treatment of severe-to-critical patients with COVID-19 demonstrated continued safety, substantial improvement in the survival rate, and &hellip; Continue reading \"SHAREHOLDER ALERT: Lowey Dannenberg, P.C., Investigates Claims on Behalf of Investors of CytoDyn Inc. and Encourages Investors to Contact the Firm\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-lowey-dannenberg-p-c-investigates-claims-on-behalf-of-investors-of-cytodyn-inc-and-encourages-investors-to-contact-the-firm\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-08T12:42:15+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMzcyNSM0MTExOTU4IzIxOTQ1MzQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-lowey-dannenberg-p-c-investigates-claims-on-behalf-of-investors-of-cytodyn-inc-and-encourages-investors-to-contact-the-firm\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-lowey-dannenberg-p-c-investigates-claims-on-behalf-of-investors-of-cytodyn-inc-and-encourages-investors-to-contact-the-firm\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SHAREHOLDER ALERT: Lowey Dannenberg, P.C., Investigates Claims on Behalf of Investors of CytoDyn Inc. and Encourages Investors to Contact the Firm","datePublished":"2021-04-08T12:42:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-lowey-dannenberg-p-c-investigates-claims-on-behalf-of-investors-of-cytodyn-inc-and-encourages-investors-to-contact-the-firm\/"},"wordCount":493,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-lowey-dannenberg-p-c-investigates-claims-on-behalf-of-investors-of-cytodyn-inc-and-encourages-investors-to-contact-the-firm\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMzcyNSM0MTExOTU4IzIxOTQ1MzQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-lowey-dannenberg-p-c-investigates-claims-on-behalf-of-investors-of-cytodyn-inc-and-encourages-investors-to-contact-the-firm\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-lowey-dannenberg-p-c-investigates-claims-on-behalf-of-investors-of-cytodyn-inc-and-encourages-investors-to-contact-the-firm\/","name":"SHAREHOLDER ALERT: Lowey Dannenberg, P.C., Investigates Claims on Behalf of Investors of CytoDyn Inc. and Encourages Investors to Contact the Firm - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-lowey-dannenberg-p-c-investigates-claims-on-behalf-of-investors-of-cytodyn-inc-and-encourages-investors-to-contact-the-firm\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-lowey-dannenberg-p-c-investigates-claims-on-behalf-of-investors-of-cytodyn-inc-and-encourages-investors-to-contact-the-firm\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMzcyNSM0MTExOTU4IzIxOTQ1MzQ=","datePublished":"2021-04-08T12:42:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-lowey-dannenberg-p-c-investigates-claims-on-behalf-of-investors-of-cytodyn-inc-and-encourages-investors-to-contact-the-firm\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-lowey-dannenberg-p-c-investigates-claims-on-behalf-of-investors-of-cytodyn-inc-and-encourages-investors-to-contact-the-firm\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-lowey-dannenberg-p-c-investigates-claims-on-behalf-of-investors-of-cytodyn-inc-and-encourages-investors-to-contact-the-firm\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMzcyNSM0MTExOTU4IzIxOTQ1MzQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMzcyNSM0MTExOTU4IzIxOTQ1MzQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-lowey-dannenberg-p-c-investigates-claims-on-behalf-of-investors-of-cytodyn-inc-and-encourages-investors-to-contact-the-firm\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SHAREHOLDER ALERT: Lowey Dannenberg, P.C., Investigates Claims on Behalf of Investors of CytoDyn Inc. and Encourages Investors to Contact the Firm"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/473570","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=473570"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/473570\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=473570"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=473570"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=473570"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}